INTRODUCTION {#s1}
============

"Omics" technologies, most prominently next-generation sequencing (NGS), have entered clinical medicine in the last decade and are expected to affect the standard of care in oncology. However, the identification of patients who truly benefit from genomics-driven approaches to clinical management and the appropriate timing of therapy are still challenging ([@GroschelMCS001180C27]). Moreover, it is currently unclear how to effectively integrate these new tools with conventional technologies such as standard histopathology, and the algorithms for integrated diagnostics and molecularly guided treatment remain to be exactly defined.

Comprehensive cancer profiling can particularly assist diagnosis and treatment planning in patients with malignancies of unresolved histology and in metastatic disease, in which the tissue of origin of the primary tumor cannot be discerned. Cancers of unknown primary (CUP) constitute 3%--5% of all cancer diagnoses and rank fourth in the causes of cancer-related deaths worldwide ([@GroschelMCS001180C34]). NGS-based molecular characterization holds the promise to gain insight into the pathobiology of these difficult-to-classify tumors. Compared to targeted sequencing of selected cancer genes, whole-exome sequencing (WES) and RNA sequencing (RNA-seq) allow for superior detection of coding sequence variants, amplifications, deletions, and structural rearrangements of chromosomes as well as their consequences on mRNA transcription. Integration of these data with mutational and transcriptional cancer profiles deposited in public genome databases, such as those generated by The Cancer Genome Atlas (TCGA) Research Network (<http://cancergenome.nih.gov>) and the International Cancer Genome Consortium (<https://icgc.org>), can aid in identifying the tissue of origin of cancers of otherwise indefinable histology and nominate candidate therapeutic targets.

Here we describe a patient with refractory, metastatic anaplastic CUP, where integrated analysis of histopathology, immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), WES, and RNA-seq revised the diagnosis and facilitated genotype-informed treatment with an immune checkpoint inhibitor (ICI) that resulted in a durable, very good partial remission.

RESULTS {#s2}
=======

A 44-yr-old Caucasian female presented to our center with metastatic CUP. Two years before presentation, she had been diagnosed with multiple metastatic lesions in the mesentery of the small intestines and the duodenojejunal flexure. At that time, the tumor lesions had been resected completely. Histopathology analyses were inconclusive, showing a high-grade neoplasm with pleomorphic tumor cells that stained positive for vimentin. MIB-1 was positive in ∼30% of the tumor cells. Following central pathology review, a preliminary diagnosis of CUP with sarcomatoid features was considered with the most likely differential diagnosis of sarcoma, not otherwise specified. The patient was treated with four cycles of doxorubicin and ifosfamide according to the EORTC (European Organisation for Research and Treatment of Cancer) 62012 protocol ([@GroschelMCS001180C15]) at an outside institution, and subsequent imaging studies revealed no evidence of disease.

Sixteen months after initial diagnosis, the patient developed progressive pain in the right shoulder, and magnetic resonance imaging (MRI) showed a mass of 4 × 2 × 2 cm in the right deltoid muscle and a second metastatic lesion of 1.5 × 2 × 2 cm in the right axilla. Incisional biopsy was performed, and subsequent histopathology assessment with repeat central review suggested metastasis of the previously diagnosed CUP rather than a secondary malignancy. After complete surgical excision of the rapidly progressing lesions, adjuvant radiotherapy was administered to the right shoulder and axilla.

Twenty-one months after initial diagnosis, follow-up MRI studies revealed five new tumor formations (left paravertebral region, right M. infraspinatus, right axilla, right M. latissimus dorsi, left chest wall). Again, surgical resection of multiple lesions was performed. However, the tumor progressed rapidly with new lesions of the right shoulder and thigh; treatment with trabectedin was initiated but had to be stopped because of progressive disease and Grade IV thrombocytopenia.

In an attempt to refine the diagnosis and inform potential therapeutic strategies, the patient was enrolled in NCT (Nationales Centrum für Tumorerkrankungen) MASTER (Molecularly Aided Stratification for Tumor Eradication Research), a cross-entity molecular stratification program for younger adults with advanced-stage cancer and patients with rare tumors ([@GroschelMCS001180C20]), and a cryopreserved biopsy of a metastatic shoulder lesion with a tumor cell content of \>90% was analyzed by WES and RNA-seq. Peripheral blood mononuclear cells served as a germline control.

WES analysis revealed a high mutational load of 341 nonsynonymous single-nucleotide variants, 39 insertion/deletions, and multiple chromosomal gains and losses ([Fig. 1](#GroschelMCS001180F1){ref-type="fig"}). Known driver mutations were detected in *TP53* (p.E135fs) and *KRAS* (p.G12S), the latter also being highly expressed on the RNA level because of a focal amplification on Chromosome 12p ([Table 1](#GroschelMCS001180TB1){ref-type="table"}). Mutations of unknown significance occurred in other cancer-related genes (e.g., *PIK3CD*, *CDKN2A*, *NCOA1*, *FAT2*, *EGFR*, *MSH3*, *ARID1A*, *MDC1*, *SETD1A*, *SETD3*, and *TET1*) (Supplemental Table S1). A focal high-level amplification on Chromosome 9p encompassed *JAK2* and *PDL1* (also known as *CD274* or *B7-H1*) together with other genes implicated in carcinogenesis ([Fig. 1](#GroschelMCS001180F1){ref-type="fig"}; [@GroschelMCS001180C16]; [@GroschelMCS001180C23]; [@GroschelMCS001180C36]; [@GroschelMCS001180C12]; [@GroschelMCS001180C14]; [@GroschelMCS001180C17]).

![*PDL1* and *GATA3* amplification in a patient with cancer of unknown primary. (*Upper* panel) Copy number plot showing chromosomal coordinates computed as a set of regions based on whole-exome sequencing data (*x*-axis) and the log~2~ ratio of copy number changes (*y*-axis). Color codes of alternating green and black regions indicate segmentation between chromosomes. (*Lower* panel) Amplified region on chromosome 9p.23--24.1.](GroschelMCS001180_F1){#GroschelMCS001180F1}

###### 

Somatic variants of potential interest

  Chr   GRCh37 position       Ref   Var  Type       Gene                 HGVS DNA reference   Predicted effect   HGVS protein reference    Genotype  dbSNP ID
  ----- -------------------- ----- ----- ---------- -------------------- -------------------- ------------------ ------------------------ ---------- -------------
  1     27099877              CA     C   FS-DEL     *ARID1A*             g.27099877CA\>C      p.N1253fs          p.Asn1253fs                 het     
  1     9770641                G     A   SNV        *PIK3CD*             g.9770641G\>A        p.S43N             p.Ser43Asn                  het     
  2     24991253               C     A   SNV        *NCOA1*              g.24991253C\>A       p.T1440N           p.Thr1440Asn                het     
  5     80160762               G     A   Splicing   *MSH3*               g.80160762G\>A                                                      het     
  5     150922306              C     G   SNV        *FAT2*               g.150922306C\>G      p.R2794S           p.Arg2794Ser                het     
  6     30671308               C     A   SNV        *MDC1*               g.30671308C\>A       p.V1857L           p.Val1857Leu                het     rs149786493
  7     55225447               G     T   Splicing   *EGFR*               g.55225447G\>T                                                      het     
  9     1461199--14398642                AMP        *PPAPDC2;PTPRD*                                                                                  
  9     21971208               C     A   Splicing   *CDKN2A*             g.21971208C\>A                                                      het     
  10    70332663               C     G   SNV        *TET1*               g.70332663C\>G       p.Q190E            p.Gln190Glu                 het     
  10    93076--14013840                  AMP        *TUBB8; PRPF18*                                                                                  
  12    19242142--30289130               AMP        *C12orf39; RASSF8*                                                                               
  12    25398285               C     T   SNV        *KRAS*               g.25398285C\>T       p.G12S             p.Gly12Ser                  het     rs1219135
  14    99927578               A     G   SNV        *SETD3*              g.99927578A\>G       p.V99A             p.Val99Ala                  het     
  16    30977120               G     C   SNV        *SETD1A*             g.30977120G\>C       p.G640R            p.Gly640Arg                 het     
  17    7577057                T    TC   FS-INS     *TP53*               g.7577057T\>TC       p.E135fs           p.Glu135fs                  het     

The complete list of somatic mutations can be found in Supplemental Table S1.

HGVS, Human Genome Variation Society; dbSNP, Database for Short Genomic Variations; AMP, amplification; FS-DEL, frameshift-deletion; FS-INS, frameshift-insertion; het, heterozygous; SNV, single-nucleotide variant.

In line with these findings, IHC and FISH analyses showed high-level amplification and subsequent overexpression of *PDL1* in the tumor cells. Histologic assessment showed substantial peritumoral infiltration of lymphocytes ([Fig. 2](#GroschelMCS001180F2){ref-type="fig"}A). Correspondingly, *PDL1* mRNA levels, as determined by RNA-seq, were highest in this tumor specimen compared to all tumor samples included in NCT MASTER (*n* = 266; [Fig. 2](#GroschelMCS001180F2){ref-type="fig"}B). A query of publicly available databases for matching cancer mutational profiles comprising *TP53* inactivation and amplification of Chromosomes 9p (*PDL1*, *JAK2*), 10p (*GATA3*), and 12p (mutant *KRAS*) as well as review of the literature suggested lung adenocarcinoma, triple-negative breast cancer (TNBC), or gastric adenocarcinoma as the most probable diagnoses ([@GroschelMCS001180C7]; [@GroschelMCS001180C9]; [@GroschelMCS001180C22]). Principal component analysis using mRNA expression profiles obtained by RNA-seq data from both TCGA and the NCT MASTER cohorts was inconclusive (data not shown). Based on these findings, we decided to challenge the initial diagnosis of a metastatic sarcoma and reevaluated tissue parameters of the current metastatic lesion. Comprehensive immunohistochemical profiling of 25 different antigens revealed strong expression of cytokeratins (as measured by AE1/3) and CK7. These data are in line with decisive histological features (e.g., focal formation of small tubular structures) and focal positivity with periodic acid--Schiff (PAS) staining leading to the diagnosis of an adenocarcinoma. We also noticed focal positivity of vimentin, which is consistent with poor differentiation and epithelial--mesenchymal transition from a histological and biological point of view, respectively. Tumor cells showed strong GATA3 expression (Supplemental Fig. 1) consistent with the genetic amplification and were negative for estrogen receptor (ER), progesterone receptor (PR), and ERBB2 (also known as HER2). In the context of poor differentiation, negativity for TTF1 and napsin does not rule out the differential diagnosis of lung adenocarcinoma but is not supportive either. Although neither IHC profiling nor molecular analyses allowed us to unequivocally pinpoint the tissue of origin, reevaluation of all parameters suggested metastatic TNBC among the top differential diagnoses, although a definitive categorization based on conventional diagnostic critera of this CUP case still remained tentative, given the clinical presentation without a primary tumor detectable in either breast, lung, or stomach.

![PDL1 protein expression, *PDL1* amplification, peritumoral lymphocyte infiltration, and *PDL1* mRNA expression in a patient with anaplastic cancer of unknown primary. (*A*) (*Left*) Photomicrograph showing PDL1 protein expression in a metastasis (scale bar, 100 µm); (*middle*) representative fluorescence in situ hybridization signal pattern showing amplification of the *PDL1* locus (green signals) relative to the centromere of Chromosome 9 (red signals); (*right*) CD4 lymphocyte staining (scale bar, 200 µm). (*B*) Ranking of 266 patient samples analyzed in the NCT MASTER study according to *PDL1* (*CD274*) mRNA levels, as determined by RNA-seq. The red bar indicates the described index patient. RPKM, reads per kilobase of exon model per million mapped reads.](GroschelMCS001180_F2){#GroschelMCS001180F2}

In similarity to our case, immune cell infiltrates and Chromosome 9p amplification have recently been described in a small cohort of TNBC ([@GroschelMCS001180C3]). We thus aimed to systematically address the question whether genomic *PDL1* gains are recurrent in TNBC and associated with elevated *PDL1* expression as observed in our case. To this end, we analyzed *PDL1* copy number variation in a TCGA cohort of 937 breast carcinomas ([Fig. 3](#GroschelMCS001180F3){ref-type="fig"}A). Copy number gains were more frequent in TNBC (43.3%) compared to hormone receptor (HR)^+^/HER2^−^, HR^+^/HER2^+^, and HR^−^/HER2^+^ breast cancer (10.9%, 10.3%, and 26.3%; *p* = 0.00045). Focal amplifications occurred in 23.6% of TNBC samples compared to 1.3%, 2.8%, and 10.5% in HR^+^/HER2^−^, HR^+^/HER2^+^, and HR^−^/HER2^+^ breast cancer specimens. *PDL1* mRNA expression analysis was performed in 934 tumors ([Fig. 3](#GroschelMCS001180F3){ref-type="fig"}B) and revealed significantly higher *PDL1* levels in tumors with *PDL1* copy number gains compared to tumors that were diploid for the *PDL1* locus (fold change, 1.25; *p* = 0.019). Furthermore, triple-negative tumors had significantly increased *PDL1* expression compared to HR^+^/HER2^−^ and HR^+^/HER2^+^ tumors (fold change, 1.49; *p* = 0.00030 and fold change, 1.42; *p* = 0.0068).

![*PDL1* DNA copy number and *PDL1* mRNA expression in the molecular subtypes of breast cancer (TCGA data sets). (*A*) *PDL1* copy number gains are more frequent in triple-negative breast cancer (TNBC) (43.3%) compared to HR^−^/HER2^+^, HR^+^/HER2^−^, and HR^+^/HER2^+^ breast cancer (26.3%, 10.9%, and 10.3%, respectively). (*B*) *PDL1* mRNA expression is higher in TNBC compared to HR^+^/HER2^−^ and HR^+^/HER2^+^ breast cancer (fold change, 1.49; *p* = 0.00030 and fold change, 1.42; *p* = 0.0068). In the beeswarm plot, each colored dot represents a tumor. The horizontal red lines indicate the first quartile, the median, and the third quartile.](GroschelMCS001180_F3){#GroschelMCS001180F3}

Both amplification and overexpression of *PDL1* and the hypermutated tumor genome provided a strong rationale for ICI treatment with the anti-PD1 monoclonal antibody pembrolizumab. The patient received pembrolizumab at a dose of 2 mg/kg body weight for repeated cycles of 3 wk starting from month 24 after initial diagnosis. At the start of treatment, baseline positron emission tomography/computed tomography (PET/CT) imaging showed widely disseminated tumor manifestations ([Fig. 4](#GroschelMCS001180F4){ref-type="fig"}A). Treatment was well tolerated and could be administered without serious side effects. After 2 mo of therapy, PET imaging showed evidence of tumor regression in most lesions while a left gluteal and a left axillar lesion increased in size and metabolic activity, likely representing an immune-mediated phenomenon. Clinically, performance status was improving rapidly, and tumor-related symptoms such as pain and motoric impairment of the left arm decreased. Six months after initiation of pembrolizumab, PET imaging results suggested a near-complete remission, formally qualifying as a very good partial remission according to Response Evaluation Criteria in Solid Tumors ([Fig. 4](#GroschelMCS001180F4){ref-type="fig"}). The patient has remained in continuous near-complete remission and free of disease-specific symptoms while being on immunotherapy at the time this report was written (14 mo after commencement of pembrolizumab).

![Response assessment after 2 and 6 mo of immunotherapy with pembrolizumab in a patient with metastatic cancer of unknown primary. (*A*) Maximum intensity plots computed from positron emission tomography/computed tomography (PET/CT) imaging showing multifocal tumor manifestations that almost vanish after 6 mo of PD1 inhibitor treatment. (*B*) Axial PET/CT images showing target lesions in the left gluteal (*upper* panels) and scapular (*lower* panels) regions. Time line from *left* to *right*: baseline, 2 mo, 6 mo.](GroschelMCS001180_F4){#GroschelMCS001180F4}

DISCUSSION {#s3}
==========

"Multi-omic" approaches and integrative analyses allow tissue-of-origin molecular profiling and can uncover new diagnostic and therapeutic opportunities in patients with high-risk and refractory cancers ([@GroschelMCS001180C27]). Matching the genetic data obtained in individual patients to the rapidly expanding public repositories of genome, exome, and transcriptome data from large cohorts of well-annotated cancers can inform histopathologic assessment, including characteristic tissue-of-origin IHC and FISH markers, and facilitate the identification of the primary cancer site in difficult cases. In our patient, molecular analysis and histopathology suggested several possible tissues of origin, but a definitive diagnosis could not be reached. This caveat may in part be explained by the limitations associated with comparison of molecular profiles of metastastic tissue with data sets obtained in treatment-naïve tumors, such as those available from TCGA.

Besides its diagnostic implications, WES can identify driver genomic alterations that are missed by interrogating single genes or a panel of cancer-related genes but may represent targets for individualized treatment. Importantly, tissue context may modulate the efficacy of therapies directed against specific molecular lesions, as shown, for example, by the variable responses to vemurafenib seen among different tumor entities with BRAF V600E mutations ([@GroschelMCS001180C28]; [@GroschelMCS001180C8]; [@GroschelMCS001180C13]; [@GroschelMCS001180C19]). Hence, responses can be difficult to predict, particularly to drugs not developed for a given indication ([@GroschelMCS001180C33]). Despite this purported predicament, targeted therapies have become the mainstay of treatment in a range of malignancies (e.g., gastrointestinal stromal tumor, chronic myeloid leukemia, or non-small-cell lung cancer), underscoring the utility of personalized genomic medicine and the incorporation of "omics" data in the clinical decision algorithm on an individual-case basis in patients otherwise refractory to conventional treatment modalities ([@GroschelMCS001180C32]; [@GroschelMCS001180C18]; [@GroschelMCS001180C29]; [@GroschelMCS001180C20]). Our diagnostic approach ruled out sarcoma and rendered the diagnosis of poorly differentiated adenocarcinoma. We were, however, unable to trace the definite tissue of origin even when employing both molecular and conventional pathology. This result may in part be explained by the fact that our case is a patient with metastatic CUP who underwent several lines of treatment before molecular profiling, a setting that hampers direct comparison with molecular profiles of treatment-naïve tumors, such as those deposited in the TCGA database. Furthermore, novel data-sharing initiatives, such as AACR (American Association for Cancer Research) Project GENIE (Genomics, Evidence, Neoplasia, Information Exchange; <http://www.aacr.org/Research/Research/Pages/aacr-project-genie.aspx>), as well as innovative interventional clinical trials, such as NCI-MATCH (National Cancer Institute-Molecular Analysis for Therapy Choice; <http://www.cancer.gov/about-cancer/treatment/clinical-trials/nci-supported/nci-match>), are expected to broaden the basis for greater individualization of therapy, particularly in the case of rare cancers and rare mutations in common cancers.

In our patient, the finding of *PDL1* amplification and overexpression in conjunction with the high mutational load, and the failure of previous conventional chemotherapeutic approaches, prompted us to administer off-label immunotherapy. Based on our patient\'s favorable clinical course, our exploration of potential differential diagnoses, and an analysis of the TCGA data set on TNBC, we speculate that ICIs might be a new treatment modality in this aggressive and clinically challenging tumor type ([@GroschelMCS001180C5]; [@GroschelMCS001180C21]). PD1-inhibitory agents are currently being investigated in TNBC in phase II/III trials that are prospectively collecting data on tumoral PDL1 expression, allowing correlative evaluation of *PDL1* copy number changes as a predictive marker ([@GroschelMCS001180C30]; [@GroschelMCS001180C31]). The mechanistic rationale underlying PD1 blockade is to reverse tumor immune evasion mediated by PDL1-PD1 engagement of the tumor with antitumor CD8^+^ T cells, which consequently become anergic. The choice of immunotherapy in our patient was supported by the high density of tumor-infiltrating lymphocytes, *PDL1* amplification resulting in strong intratumoral PDL1 expression both on the RNA and protein level, and a high mutational load, which was reported as being predictive for response to ICI in a range of cancers ([@GroschelMCS001180C10]; [@GroschelMCS001180C21]; [@GroschelMCS001180C25]). Although future studies are needed to further establish robust and reliable determinants of response to ICI ([@GroschelMCS001180C6]; [@GroschelMCS001180C24]), *PDL1* amplification might serve as a rapidly available and inexpensive surrogate marker across histologic entities, as supported by the striking therapeutic activity of PD1 blockade in TNBC (this study) and refractory classical Hodgkin lymphoma ([@GroschelMCS001180C1]; [@GroschelMCS001180C26]) characterized by Chromosome 9p24.1 gain. In a recent pan-cancer analysis, *PDL1* gains were shown to occur in many cancer types and to result in *PDL1* mRNA overexpression in some tumors ([@GroschelMCS001180C4]). Moreover, a *PDL1* core amplification region of 7.8 Mb on Chromosome 9p that extended to the telomere was identified, consistent with the finding in this report. *JAK2* is coamplified in this region ([@GroschelMCS001180C2]), which is of potential interest, because JAK2 has been reported previously as a positive regulator of *PDL1* and *PDL2* genes ([@GroschelMCS001180C11]). Inactivating *JAK2* mutations have recently been implicated in acquired resistance to PD1 inhibitor treatment and immune evasion of cancer cells, possibly related to down-regulation of *PDL1* and antigen presentation as a consequence of abolished interferon signaling due to loss-of-function alterations in JAK2 ([@GroschelMCS001180C35]).

In summary, our observations show that clinical NGS can uncover new therapeutic targets and may eventually help to change the management of a considerable number of patients with CUP. The steadily decreasing turnaround time of WES and even whole-genome analysis, declining sequencing costs, and continuous workflow standardizations create a strong imperative to implement this methodology for the diagnostic workup of CUP patients. Furthermore, our experience illustrates how integration of different methods can optimize diagnostics and identify targets for intervention especially in cases in which it is difficult to arrive at a consensus diagnosis by conventional means.

METHODS {#s4}
=======

WES, RNA-seq, and Bioinformatic Analysis {#s4a}
----------------------------------------

Exome capture was performed using SureSelect Human All Exon V5+UTRs in-solution capture reagents (Agilent). One and one-half micrograms of genomic DNA was sheared sonically to 150--200 bp (paired-end) insert size with a Covaris S2 device. Two hundred and fifty nanograms of Illumina adapter-containing library was hybridized with exome baits at 65°C for 16 h. Paired-end sequencing (101 bp) was performed with a HiSeq 2500 instrument (Illumina) in a rapid mode. RNA-seq libraries were prepared using the TruSeq RNA Sample Preparation Kit v2 (Illumina). Briefly, mRNA was purified from 1 µg total RNA using oligo(dT) beads, poly(A)^+^ RNA was fragmented to 150 bp and converted into cDNA, and cDNA fragments were end-repaired, adenylated on the 3′ end, adapter-ligated, and amplified with 12 cycles of polymerase chain reaction. The final libraries were validated using a Qubit 2.0 Fluorometer (Life Technologies) and a Bioanalyzer 2100 system (Agilent). Paired-end sequencing (2 × 101 bp) was performed with a HiSeq 2500 instrument (Illumina) in a rapid mode. Sequencing data were analyzed using a previously reported bioinformatics workflow ([@GroschelMCS001180C20]; see [Table 2](#GroschelMCS001180TB2){ref-type="table"} for coverage metrics).

###### 

Whole-exome sequencing (WES) and RNA sequencing (RNA-seq) coverage metrics

               WES           RNA-seq                                
  ------------ ------------- --------- ----- -------- ------------- -------
  Buffy coat   94,580,016    99.49     5.6   125.04       n.a.       n.a.
  Tumor        113,842,258   99.58     7.4   149.78    243,198,700   94.14

n.a., not applicable.

Triple-Negative Breast Cancer Data Set {#s4b}
--------------------------------------

Breast cancer data sets (study brca_tcga_pub2015) including data on DNA copy number status (GISTIC) and mRNA expression (RNA Seq V2 RSEM) of *PDL1* were retrieved from the cBioPortal for Cancer Genomics (<http://www.cbioportal.org/public-portal>) and analyzed as described previously ([@GroschelMCS001180C4]). Immunohistochemistry data for ER, PR, and HER2 as well as FISH data for HER2 were retrieved from the TCGA data portal (<https://tcga-data.nci.nih.gov>). The study cohort comprised 937 breast carcinomas with available copy number data. Cases were classified into molecular subtypes: 597 (63.7%) HR^+^/HER2^−^ tumors, 145 (15.5%) HR^+^/HER2^+^ tumors, 38 HR^−^/HER2^+^ tumors (4.1%), and 157 (16.8%) HR^−^/HER2^−^ tumors. RNA-seq data were available for 934 of these tumors.

Immunohistochemistry and Fluorescence In Situ Hybridization {#s4c}
-----------------------------------------------------------

Immunohistochemical staining was performed on formalin-fixed and paraffin-embedded whole-tissue slides using a BenchMark XT device (Ventana Medical Systems) according to quality-controlled standard procedures. After antigen retrieval, the following primary antibodies were used: AE1/3: 1:100 dilution, DAKO (\#M3515); GATA3: ready to use, Ventana (\#760--4897); CK7: 1:50 dilution, DAKO (\#M7018); PDL1: 1:100 dilution, Spring (\#07309457001); CD4 mouse monoclonal antibody: 1:20 dilution, Novocastra/Leica (clone 1F6); napsin: 1:400 dilution, Novacastra/Leica (clone IP64, \#NCL-L-Napsin A); TTF1: 1:100 dilution, Novocastra/Leica (clone SPT24, \#NCL-L-TTF1). Either 3,3′-diaminoenzidine peroxide substrate or 3-amino-9-ethylcarbazole served as chromogens.

FISH using a commercially available dual color probe for the *PDL1* (*CD274*) gene (Zytovision; \# Z-2179--200) was performed on whole slides according to the manufacturer\'s instructions. Four-micrometer-thick sections were cut, mounted on SuperFrost slides, and deparaffinized. The *PDL1* probe was labeled with a green fluorochrome and the classical satellite III region of Chromosome 9 (CEN9, D9Z3) was labeled with an orange fluorochrome.

ADDITIONAL INFORMATION {#s5}
======================

Data Deposition and Access {#s5a}
--------------------------

WES and RNA-seq data derived from the patient specimen have been deposited at the European Genome-phenome Archive (EGA; <https://www.ebi.ac.uk/ega/>), which is hosted by the European Bioinformatics Institute (EBI), under accession number EGAS00001001846. Point substitution variants were submitted to the Catalogue of Somatic Mutations in Cancer (COSMIC; <http://cancer.sanger.ac.uk/cosmic>, identifier COSP41747).
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